{
    "clinical_study": {
        "@rank": "147813", 
        "acronym": "Ach-ALN", 
        "arm_group": [
            {
                "arm_group_label": "Fixed Combination of Budesonide and formoterol", 
                "arm_group_type": "Experimental", 
                "description": "Group 1 (experimental): Fixed Combination of Budesonide and formoterol"
            }, 
            {
                "arm_group_label": "Budesonide", 
                "arm_group_type": "Active Comparator", 
                "description": "Group 2 (comparator): Budesonide"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and safety of a fixed-dose, single-capsule\n      budesonide(400\u00b5g)-formoterol(12\u00b5g) combination, in comparison with budesonide alone, both\n      delivered via a dry powder inhaler, in 181 patients with uncontrolled asthma.This was\n      Randomized, double-blind, multicenter, phase III, parallel clinical trial."
        }, 
        "brief_title": "Evaluation of the Efficacy and Safety of a Fixed-dose, Single-capsule Budesonide-formoterol Combination in Uncontrolled Asthma", 
        "completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "the age of the patients ranged from 18 to 77 years. After a run-in period of 4 weeks, during\n      which all of the patients received budesonide twice a day, they were randomized into one of\n      the treatment groups for 12 weeks, twice a day.\n\n      The primary outcome measures were FEV1, FVC and morning PEF. We performed an\n      intention-to-treat analysis of the data."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of uncontrolled asthma\n\n          -  Age ranged from 18 to 77 years\n\n          -  Nonsmokers\n\n        Exclusion Criteria:\n\n          -  Use of oral corticosteroids, anti-leukotrienes, immunoglobulins, beta blockers,\n             digitalis, amiodarone, antifungals, antidepressants, monoamine oxidase inhibitors and\n             tricyclics during the standardization\n\n          -  Atrial fibrillation, Flutter, severe and complex tachyarrhythmias atrioventricular\n             block 1,2 and 3\n\n          -  Diabetes mellitus\n\n          -  Pregnancy\n\n          -  Neuropsychiatric diseases\n\n          -  Pulmonary malformations, tuberculosis, Cystic fibrosis\n\n          -  Immunosuppressive treatment\n\n          -  Hospitalization for asthma or respiratory infection in last 30 days\n\n          -  Severe systemic disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "77 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "181", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01676987", 
            "org_study_id": "Ach-ALN-04(7/07)"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fixed Combination of Budesonide and formoterol", 
                "description": "Delivered dry powder inhaler for 12 weeks.", 
                "intervention_name": "Fixed combination of budesonide and formoterol", 
                "intervention_type": "Drug", 
                "other_name": "Group 1 (experimental): Budesonide and formoterol"
            }, 
            {
                "arm_group_label": "Budesonide", 
                "description": "Delivered dry powder inhaler for 12 weeks.", 
                "intervention_name": "Budesonide", 
                "intervention_type": "Drug", 
                "other_name": "Group 2 (comparator): Budesonide"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Budesonide", 
                "Formoterol", 
                "Symbicort", 
                "Adrenergic beta-2 Receptor Agonists"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Asthma", 
            "Budesonide", 
            "Adrenergic beta-2 receptor agonists."
        ], 
        "lastchanged_date": "August 30, 2012", 
        "number_of_arms": "2", 
        "official_title": "Evaluation of the Efficacy and Safety of a Fixed-dose, Single-capsule Budesonide-formoterol Combination in Uncontrolled Asthma:a Randomized, Double-blind, Multicenter, Controlled Clinical Trial.", 
        "overall_official": {
            "affiliation": "NUPAIVA Asthma Research Center, UFSC- Brazil", 
            "last_name": "Em\u00edlio Pizzichini", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Brazil: National Health Surveillance Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "the primary outcome Measures were FEV1(forced expiratory volume in one second), FVC(forced vital capacity)and morning PEF (peak expiratory flow).", 
            "measure": "Evaluation of the efficacy and safety of a fixed-dose, single capsule budesonide-formoterol combination in comparison with budesonide alone in patients with uncontrolled asthma", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01676987"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Ache Laboratorios Farmaceuticos S.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ache Laboratorios Farmaceuticos S.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}